Skip to main content
Advisory Service

AI & Digital Strategy for Regulated Industries

Practical AI adoption that works within pharma compliance frameworks - no hype, just results

MIT

Executive Certificate in Digital Business (2024)

3

IMD digital strategy programs completed

#1

AI-enabled content supply chain in pharma

AI is transforming every industry - but in pharma, adoption must work within strict regulatory and compliance frameworks. Dr. Kurr helps organizations move beyond the AI hype to identify practical, governed use cases that deliver measurable value. His approach combines hands-on experience building AI-enabled operations at Boehringer Ingelheim with academic partnerships in AI and data science, and executive education from MIT Sloan's Digital Business program.

AI That Fits Governed Workflows

The biggest challenge in pharma AI adoption is not the technology - it is governance. Medical, legal, and regulatory (MLR) review workflows, pharmacovigilance requirements, and data privacy regulations create constraints that most AI vendors do not understand. Dr. Kurr has built AI-enabled operations inside these constraints. At Boehringer Ingelheim, he integrated AI and data science into go-to-market operations while maintaining full compliance with pharma-specific regulatory requirements. The key is human-in-the-loop governance design - ensuring that AI accelerates human decision-making without removing accountability.

Agentic AI for Commercial Operations

The next frontier is agentic AI - autonomous AI systems that can execute multi-step workflows with minimal human intervention. In pharma commercial operations, this means AI agents that can draft content, route it through approval workflows, personalize omnichannel engagement, and optimize field force deployment. Dr. Kurr helps organizations develop agentic AI strategies that are both ambitious and realistic - identifying which workflows are ready for autonomy, which require human oversight, and how to build the governance frameworks that make agentic AI safe in regulated environments.

Content Supply Chain Automation

Dr. Kurr built what external benchmarks called one of the leading content supply chains in the pharma industry. AI played a central role - from automated content generation and localization to intelligent routing and performance analytics. Content supply chain automation in pharma requires understanding the full value chain: from medical review through creative production, localization, regulatory approval, and multichannel distribution. Dr. Kurr's experience covers the entire chain, not just point solutions.

AI Readiness and Roadmap

Most organizations are not ready for AI - not because the technology is not available, but because their data, processes, and governance structures are not mature enough to support it. Dr. Kurr's AI readiness assessment evaluates organizational maturity across five dimensions: data infrastructure, process standardization, governance frameworks, talent and skills, and change readiness. The result is a prioritized roadmap that sequences AI adoption based on organizational readiness, not technology trends. His executive education at MIT Sloan (Digital Business, 2024) and his AI and Data Science fellowship partnership with Eberhard Karls Universität Tübingen provide the academic foundation for this work.

What This Includes

  • AI readiness assessment and roadmap
  • Agentic AI strategy for commercial operations
  • MLR workflow optimization with AI
  • Content supply chain automation
  • Human-in-the-loop governance design
Questions

Frequently Asked Questions

The biggest challenge in pharma AI adoption is not the technology - it is governance. Medical, legal, and regulatory (MLR) review workflows, pharmacovigilance requirements, and data privacy regulations create constraints that most AI vendors do not understand. Dr. Kurr has built AI-enabled operation...

The next frontier is agentic AI - autonomous AI systems that can execute multi-step workflows with minimal human intervention. In pharma commercial operations, this means AI agents that can draft content, route it through approval workflows, personalize omnichannel engagement, and optimize field for...

Dr. Kurr built what external benchmarks called one of the leading content supply chains in the pharma industry. AI played a central role - from automated content generation and localization to intelligent routing and performance analytics. Content supply chain automation in pharma requires understan...

Most organizations are not ready for AI - not because the technology is not available, but because their data, processes, and governance structures are not mature enough to support it. Dr. Kurr's AI readiness assessment evaluates organizational maturity across five dimensions: data infrastructure, p...

Let’s Connect

Interested in ai & digital strategy for regulated industries or exploring how Dr. Kurr can support your organization?